Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Enrolling by invitation Phase 3 Interventional

A Study to Evaluate the Long-term Safety, Tolerability, and Efficacy of Subcutaneous Sonelokimab in Participants With Psoriatic Arthritis

ClinicalTrials.gov ID: NCT07223138

Public ClinicalTrials.gov record NCT07223138. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Sep 9, 2026, 1:45 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

This is a study to demonstrate the long-term safety, tolerability and clinical efficacy of sonelokimab in the treatment of patients with psoriatic arthritis who completed a parental study (M1095-PSA-301 or M1095-PSA-302)

Study identification

NCT ID
NCT07223138
Recruitment status
Enrolling by invitation
Study type
Interventional
Phase
Phase 3
Lead sponsor
MoonLake Immunotherapeutics AG
Industry
Enrollment
1,560 participants

Conditions and interventions

Interventions

Drug

Eligibility (public fields only)

Age range
18 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Nov 12, 2025
Primary completion
Feb 3, 2028
Completion
Feb 3, 2028
Last update posted
Jun 10, 2026

2025 – 2028

United States locations

U.S. sites
16
U.S. states
9
U.S. cities
16
Facility City State ZIP Site status
Clinical Site Avondale Arizona 85392
Clinical Site Mesa Arizona 85210
Clinical Site Phoenix Arizona 85032
Clinical Site Tucson Arizona 85748
Clinical Site Jonesboro Arkansas 72401
Clinical Site Upland California 91786
Clinical Site Avon Park Florida 33825
Clinical Site Clearwater Florida 33765
Clinical Site Tampa Florida 33607
Clinical Site Charlotte North Carolina 28262
Clinical Site Leland North Carolina 28451
Clinical Site Middleburg Heights Ohio 44130
Clinical Site Duncansville Pennsylvania 16635
Clinical Site Memphis Tennessee 38119
Clinical Site Baytown Texas 77521
Clinical Site Lubbock Texas 79424

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT07223138, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Jun 10, 2026 · Synced Sep 9, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT07223138 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →